limestone has been researched along with Hyperphosphatemia in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (24.56) | 29.6817 |
| 2010's | 39 (68.42) | 24.3611 |
| 2020's | 4 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Chariyavilaskul, P; Eiam-Ong, S; Katavetin, P; Leelahavanichkul, A; Phannajit, J; Praditpornsilpa, K; Puapatanakul, P; Sitticharoenchai, P; Sukkumme, W; Susantitaphong, P; Takkavatakarn, K | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Fujikawa, K; Hiroyoshi, T; Isoyama, N; Kuro-O, M; Matsuyama, H; Miura, Y; Nagata, Y; Nakamura, K | 1 |
| Akizawa, T; Fukagawa, M; Fukushima, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Bosch, J; Gao, P; Garg, AX; Girard, L; Manns, BJ; Mazzetti, A; Parfrey, P; Rabbat, CG; Rathe-Skafel, A; Smyth, A; Tennankore, K; Tyrwhitt, J; Wald, R; Walsh, M; Yan, AT | 1 |
| Garg, AX; Habbous, S; Martin, J; Przech, S; Sarma, S | 1 |
| Gao, Y; Li, Y; Lv, C; Wang, G; Wang, Z | 1 |
| Collins, MT; Gafni, RI | 1 |
| Bartko-Winters, S; Bernard, L; Di Iorio, B; Fenton, A; Hutchison, C; Thompson, M | 1 |
| Chennasamudram, SP; Noor, T; Vasylyeva, TL | 1 |
| Furui, H; Gotoh, J; Hattori, M; Horie, T; Iida, J; Kawamura, A; Kukita, K; Meguro, J; Onodera, K; Tamaki, T; Tsuchihashi, S; Yonekawa, M | 1 |
| Hasegawa, Y; Kamo, Y; Kikuchi, N; Matsuda, E; Sekino, H; Sekino, M; Takeuchi, K | 1 |
| Hong, Z; Ishizu, T; Kaneko, Y; Matsunaga, T; Taru, Y | 1 |
| Chatterley, T; Dorgan, M; Fitchett, D; Jamal, SA; Lok, CE; Mendelssohn, DC; Raggi, P; Tsuyuki, RT; Vandermeer, B | 1 |
| Caldera, F; Deshmukh, K; Shende, P; Trotta, F | 1 |
| Bennett-Jones, D; Dasgupta, I; McVeigh, G; Shroff, R | 1 |
| Galani, VJ; Prajapati, VA; Shah, PR | 1 |
| Hara, K; Kishi, Y; Kurosawa, N; Obara, Y; Takada, D; Yamashiro, H | 1 |
| Bell, C; Bellasi, A; Cipriani, F; Di Iorio, B; Molony, D; Ruggeri, M; Russo, D | 1 |
| Bellasi, A; Cipriani, F; Di Iorio, B; Ruggeri, M; Russo, D | 1 |
| Huang, Y; Mao, Z; Wang, Y; Xie, G; Yang, B; Zhang, H | 1 |
| Fang, W; Gu, AP; Jiang, N; Lin, AW; Ni, ZH; Qian, JQ; Yang, XX; Yuan, JZ | 1 |
| Biyani, M; Imtiaz, R; Lavoie, S; Leung, S; McCormick, B; Wagner, J; Zimmerman, D | 1 |
| Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S | 1 |
| Drożdż, D; Drożdż, T; Kwinta, P; Miklaszewska, M; Pietrzyk, JA; Sztefko, K; Zachwieja, K; Łatka, M | 1 |
| Gutekunst, L | 1 |
| Huang, CC; Lin, HH; Liou, HH; Wu, MS | 1 |
| Bose, S; Finkelstein, E; Nguyen, HV | 1 |
| Rizk, R | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Kaneda, H; Ogata, H | 1 |
| Hamada, C; Hasegawa, H; Higuchi, C; Hiramatsu, M; Hosoya, T; Itami, N; Kasai, K; Kawaguchi, Y; Kawanishi, H; Kubota, M; Masakane, I; Minakuchi, J; Mitarai, T; Nakao, T; Suzuki, H; Tomo, T; Yamamoto, H | 1 |
| Shigematsu, T | 1 |
| Koiwa, F; Sato, Y | 1 |
| Yokoyama, K | 1 |
| Taniguchi, M | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K | 1 |
| Shigematsu, T; Skaguchi, T | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Fan, Q; Liu, J; St Peter, WL; Weinhandl, E | 1 |
| Chew, D; Kidder, AC | 1 |
| Rees, L; Shroff, RC | 1 |
| Assimon, MM; Mousa, S; Pai, AB; Shaker, O | 1 |
| Barré, P; Hercz, G; Hirsch, D; Hodsman, A; Leblanc, M; Levin, A; Lok, C; Morton, AR; Murphy, S; Reslerova, M | 1 |
| Elashoff, R; Gales, B; Jüppner, H; Pereira, RC; Sahney, S; Salusky, IB; Wang, HJ; Wesseling-Perry, K | 1 |
| Kestenbaum, B; Liu, J; Winkelmayer, WC | 1 |
| Damment, SJ | 1 |
| Negi, S; Shigematsu, T | 1 |
| Jean, G | 1 |
| Carroll, R; Cervelli, MJ; McDonald, SP; Meade, A; Shaman, A | 1 |
| Blake, PG; Filler, G; Roach, E; Sharma, AP; Yang, L; Yasin, A | 1 |
| Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T | 1 |
| Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K | 1 |
| Choi, HY; Lee, HY; Lee, YK; Shin, SK | 1 |
| Chaplin, S; Elgazzar, HA; Goldsmith, D; Molony, DA; Taylor, MJ | 1 |
| Date, T; Funakoshi, S; Hashiguchi, J; Itoh, K; Kono, T; Kubo, H; Masaki, K; Nakano, H; Shigematsu, T; Tanaka, M; Uchino, J | 1 |
| Harland, C; Wrong, O | 1 |
17 review(s) available for limestone and Hyperphosphatemia
| Article | Year |
|---|---|
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Topics: Adult; Aged; Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer | 2018 |
Hypoparathyroidism.
Topics: Administration, Intravenous; Adult; Calcitriol; Calcium; Calcium Carbonate; Female; Humans; Hyperphosphatemia; Hypocalcemia; Hypoparathyroidism; Parathyroid Hormone; Pregnancy; Pregnancy Complications | 2019 |
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
Topics: Acetates; Aged; Calcium Carbonate; Calcium Compounds; Cause of Death; Chelating Agents; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chelation Therapy; Diet Therapy; Evidence-Based Medicine; Humans; Hyperphosphatemia; Nephrology; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; United States | 2013 |
Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis.
Topics: Acetates; Adult; Calcium Carbonate; Calcium Compounds; Female; Humans; Hyperphosphatemia; Male; Renal Dialysis | 2015 |
An Update on Phosphate Binders: A Dietitian's Perspective.
Topics: Aluminum Hydroxide; Calcium Carbonate; Diet; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Nutritionists; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Topics: Administration, Oral; Aluminum Compounds; Calcium Carbonate; Chronic Disease; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2009 |
[Management of hyperphosphatemia ; phosphate-binder].
Topics: Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Polyamines; Sevelamer; Vascular Diseases | 2009 |
[Use of phosphate binder in predialysis patients].
Topics: Calcium Carbonate; Chronic Disease; Dialysis; Drug Approval; Humans; Hyperphosphatemia; Japan; Kidney Diseases; Lanthanum; Polyamines; Prognosis; Sevelamer | 2009 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
Topics: Acetates; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Chelating Agents; Drug Design; Gels; Humans; Hyperphosphatemia; Lanthanum; Macromolecular Substances; Phosphorus, Dietary; Polyamines; Polymers; Renal Dialysis; Sevelamer | 2009 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
Treatment options for hyperphosphatemia in feline CKD: what's out there?
Topics: Animals; Calcium Carbonate; Cat Diseases; Cats; Chelating Agents; Diet; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Parathyroid Hormone; Phosphates; Phosphorus; Prognosis | 2009 |
Phosphate binders in CKD: chalking out the differences.
Topics: Calcium; Calcium Carbonate; Child; Diet; Humans; Hyperparathyroidism; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2010 |
The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Polyamines; Renal Dialysis; Sevelamer | 2010 |
[How to manage mineral metabolism disorders in renal failure].
Topics: Aged; Alkaline Phosphatase; Bone Density; Calcimimetic Agents; Calcitriol; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Combined Modality Therapy; Diabetic Nephropathies; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Male; Parathyroid Hormone; Phosphorus, Dietary; Predictive Value of Tests; Renal Replacement Therapy | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Topics: Aluminum Hydroxide; Calcium Carbonate; Chelating Agents; Cholestyramine Resin; Chronic Disease; Diet, Protein-Restricted; Drug Design; Humans; Hyperphosphatemia; Ion Exchange Resins; Kidney Diseases; Lanthanum; Phosphorus, Dietary; Polyamines; Sevelamer | 2012 |
23 trial(s) available for limestone and Hyperphosphatemia
| Article | Year |
|---|---|
Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial.
Topics: Calcium Carbonate; Chelating Agents; Cresols; Female; Humans; Hyperphosphatemia; Indican; Male; Middle Aged; Renal Insufficiency, Chronic; Sevelamer; Sulfuric Acid Esters; Uremic Toxins | 2021 |
Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
Topics: Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Dialysis; Treatment Outcome; Vascular Calcification | 2022 |
The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Calcium; Calcium Carbonate; Drug Substitution; Female; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis | 2020 |
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Topics: Aged; Calcium Carbonate; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Hip Fractures; Humans; Hyperparathyroidism; Hyperphosphatemia; Incidence; Japan; Lanthanum; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis; Vascular Calcification | 2021 |
Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
Topics: Aged; Biomarkers; Calcium Carbonate; Canada; Chelating Agents; Drug Dosage Calculations; Drug Monitoring; Feasibility Studies; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Nomograms; Phosphates; Pilot Projects; Quality of Life; Renal Dialysis; Time Factors; Treatment Outcome | 2017 |
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Calcium Carbonate; Charcoal; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vascular Calcification | 2019 |
Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.
Topics: Adult; Aged; Biomarkers; Calcium; Calcium Carbonate; Chelating Agents; Cross-Over Studies; Cytokines; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Hyperphosphatemia; Inflammation; Lipids; Male; Middle Aged; Peritoneal Dialysis; Phosphates; Polyamines; Serum Albumin; Sevelamer; Treatment Outcome | 2013 |
Study of prolonged administration of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2013 |
Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Parathyroid Hormone; Phosphates; Polyamines; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors | 2013 |
Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Topics: Aged; Calcium; Calcium Carbonate; Chelating Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
Topics: Aged; Antacids; Calcium Carbonate; Chelating Agents; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Italy; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Sevelamer; Treatment Outcome | 2015 |
Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Calcium; Calcium Carbonate; Cooking; Diet; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Nutrition Assessment; Peritoneal Dialysis; Phosphates; Phosphorus, Dietary; Prospective Studies; Serum Albumin; Young Adult | 2015 |
Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
Topics: Administration, Oral; Calcium Carbonate; Chelating Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Phosphates; Prospective Studies; Treatment Outcome | 2015 |
Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients.
Topics: Aged; alpha-2-HS-Glycoprotein; C-Reactive Protein; Calcium; Calcium Carbonate; Chelating Agents; Cholesterol, LDL; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sevelamer; Treatment Outcome; Triglycerides | 2016 |
Design and baseline characteristics of the LANDMARK study.
Topics: Aged; Biomarkers; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Clinical Protocols; Disease-Free Survival; Female; Humans; Hyperphosphatemia; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Topics: Antacids; Calcium Carbonate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2008 |
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Follow-Up Studies; Health Care Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Medicaid; Medicare; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Treatment Outcome; United States | 2009 |
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Topics: Adolescent; Bone and Bones; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Drug Therapy, Combination; Ergocalciferols; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Longitudinal Studies; Male; Osteogenesis; Parathyroid Hormone; Polyamines; Sevelamer | 2011 |
Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Biomarkers; Calcium; Calcium Carbonate; Chelating Agents; Cross-Over Studies; Cross-Sectional Studies; Double-Blind Method; Drug Interactions; Female; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Pantoprazole; Parathyroid Hormone; Phosphates; Proton Pump Inhibitors; Renal Dialysis; South Australia; Time Factors; Treatment Outcome | 2012 |
Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Carbonate; Chelating Agents; Chi-Square Distribution; Cross-Over Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperphosphatemia; Isoenzymes; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vitamin D | 2012 |
Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Topics: Adult; Calcium; Calcium Carbonate; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Prospective Studies; Republic of Korea | 2013 |
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Chelating Agents; Drug Therapy, Combination; Epichlorohydrin; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Imidazoles; Japan; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Polyamines; Prospective Studies; Renal Dialysis; Resins, Synthetic; Sevelamer | 2008 |
17 other study(ies) available for limestone and Hyperphosphatemia
| Article | Year |
|---|---|
Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Topics: Calcium Carbonate; Chelating Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Male; Markov Chains; Middle Aged; Polyamines; Quality-Adjusted Life Years; Regression Analysis; Renal Insufficiency, Chronic; Sevelamer; United Kingdom | 2013 |
Novel cyclodextrin nanosponges for delivery of calcium in hyperphosphatemia.
Topics: Calcium; Calcium Carbonate; Cyclodextrins; Delayed-Action Preparations; Drug Carriers; Gastric Juice; Humidity; Hydrogen-Ion Concentration; Hyperphosphatemia; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Phosphates; Potassium Compounds | 2013 |
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Topics: Acetates; Adult; Biomarkers; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
Topics: Aged; Calcium Carbonate; Cause of Death; Chelating Agents; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Hyperphosphatemia; Male; Middle Aged; Mortality; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose | 2016 |
[Do we successfully treat anemia and calcium-phosphate disorders in children with chronic kidney disease at the beginning of the twenty-first century?].
Topics: Adolescent; Anemia; Calcium Carbonate; Child; Disease Progression; Erythropoietin; Female; Humans; Hydroxycholecalciferols; Hyperphosphatemia; Hypocalcemia; Male; Parathyroid Hormone; Renal Insufficiency, Chronic; Treatment Outcome | 2015 |
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Male; Markov Chains; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Singapore; Treatment Outcome; Young Adult | 2016 |
Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.
Topics: Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Humans; Hyperphosphatemia; Renal Insufficiency, Chronic; Sevelamer | 2016 |
Differences in corrective mode for divalent ions and parathyroid hormone between standard- and low-calcium dialysate in patients on continuous ambulatory peritoneal dialysis--result of a nationwide survey in Japan.
Topics: Adult; Aged; Antacids; Calcium; Calcium Carbonate; Dialysis Solutions; Drug Prescriptions; Health Surveys; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphorus; Surveys and Questionnaires; Vitamin D; Vitamins | 2008 |
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
Topics: Adenine; Animals; Aortic Diseases; Biomarkers; Blood Urea Nitrogen; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Cholecalciferol; Chronic Disease; Creatinine; Disease Models, Animal; Disease Progression; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Diseases; Male; Parathyroid Hormone; Phosphates; Polyamines; Rats; Rats, Wistar; Sevelamer; Severity of Illness Index; Time Factors | 2009 |
Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?
Topics: Aged; Aluminum Hydroxide; Calcium; Calcium Carbonate; Chelating Agents; Decision Making; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Prevalence; Quality Control; Renal Dialysis; Reproducibility of Results; Retrospective Studies; Sevelamer | 2010 |
Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients.
Topics: Acetates; Adult; Aged; Calcium Carbonate; Calcium Compounds; Cohort Studies; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Prospective Studies; Renal Dialysis | 2011 |
Pharmacology of the phosphate binder, lanthanum carbonate.
Topics: Aluminum Hydroxide; Animals; Calcium; Calcium Carbonate; Chelating Agents; Dogs; Drug Evaluation, Preclinical; Feces; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mice; Phosphates; Phosphorus Radioisotopes; Polyamines; Rats; Rats, Sprague-Dawley; Sevelamer | 2011 |
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Topics: Adult; Aged; Antacids; Calcium; Calcium Carbonate; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome; Young Adult | 2012 |
High prevalence of elevated lead levels in pediatric dialysis patients.
Topics: Adolescent; Antacids; Calcium Carbonate; Child; Child, Preschool; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hyperphosphatemia; Infant; Lead; Male; Mass Spectrometry; Prevalence; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2012 |
An economic evaluation of sevelamer in patients new to dialysis.
Topics: Antacids; Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Markov Chains; Polyamines; Quality-Adjusted Life Years; Renal Dialysis; Sevelamer | 2008 |
Sevelamer.
Topics: Calcium Carbonate; Chelating Agents; Cost Savings; Drug Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Polyamines; Renal Dialysis; Sensitivity and Specificity; Sevelamer; Treatment Outcome; United Kingdom | 2008 |